5,052
Views
5
CrossRef citations to date
0
Altmetric
Rapid Communication

Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series

ORCID Icon, , , , , , , & show all

References

  • Van Bueren L, Jakobs D, Kaldenhoven N, et al. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. Blood. 2014;124:3474. DOI:10.1182/blood.V124.21.3474.3474.
  • Jiang H, Acharya C, An G, et al. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia. 2016;30:399–408.
  • Martin TG, Corzo K, Chiron M, et al. Therapeutic opportunities with pharmacological inhibition of CD38 with isatuximab. Cells. 2019;8:1522. DOI:10.3390/cells8121522.
  • Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394(10214):2096–2107.
  • National Institute for Health and Care Excellence. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma. 2020; [last accessed 2021 June 22]. Available from: https://www.nice.org.uk/guidance/TA658.
  • Becnel MR, Horowitz SB, Thomas SK, et al. Descriptive analysis of isatuximab use following prior daratumumab in patients with relapsed/refractory multiple myeloma. Blood. 2020;136:20–21.
  • Mikhael J, Belhadj-Merzoug K, Hulin C, et al. A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood Cancer J. 2021;11:89. DOI:10.1038/s41408-021-00478-4.
  • Common Terminology Criteria for Adverse Events (CTCAE) v5. European Organisation for Research and Treatment of Cancer. 2017. [last accessed 2021 August 9]. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5 ( 7.pdf.